诺诚健华Autoimmune pipeline holds potential for

招银国际
May 15, 2025

一、公司业绩表现与核心产品进展InnoCare Pharma(9969HK)在2025年第一季度交出了稳健的财务表现,营收达到3.81亿元人民币,其核心产品orelabrutinib销售额同比增长89%,环比增长1%至3.11亿元人民币。这一增长主要得益于MZL(边缘区淋巴瘤)适应症的持续市场渗透。Orelabrutinib是目前中国唯一获批并纳入国家医保目录(NRDL)用于MZL治疗的BTK...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10